insulin aspart

insulin aspart is a rapid-acting insulin analogue used for the management of hyperglycemia in individuals with diabetes mellitus. It is produced using recombinant DNA technology, where the amino acid proline at position B28 is substituted with aspartic acid, a modification that reduces the molecule's tendency to self-associate into hexamers. This structural change allows for faster absorption into the bloodstream following subcutaneous injection, leading to a more rapid onset and shorter duration of action compared to regular human insulin. The drug is marketed under brand names such as NovoRapid and NovoLog by the Danish pharmaceutical company Novo Nordisk.

Medical uses

insulin aspart is primarily indicated for the control of postprandial blood glucose levels in adults and children with type 1 diabetes and in adults with type 2 diabetes. It is typically administered just before or immediately after a meal to mimic the body's natural prandial insulin release. The medication can be used in conjunction with longer-acting basal insulin regimens, such as insulin detemir or insulin glargine, to provide comprehensive glycemic control. It is also approved for use in continuous subcutaneous insulin infusion via insulin pump therapy and, in some regions, for intravenous administration in hospital settings under medical supervision, such as during surgery or treatment for diabetic ketoacidosis.

Adverse effects

The most common adverse effect associated with insulin aspart is hypoglycemia, which can range from mild symptoms like tremor and sweating to severe events requiring assistance from another person or administration of glucagon. Injection site reactions, including lipodystrophy, pruritus, and erythema, may occur but are generally mild. As with all exogenous insulin, there is a risk of weight gain and, very rarely, systemic allergic reactions. Patients should be monitored for signs of hypokalemia, particularly when used alongside other medications like diuretics or in conditions such as renal impairment.

Pharmacology

The pharmacodynamic action of insulin aspart stems from its binding to the insulin receptor on target cells, such as those in liver, muscle, and adipose tissue, which promotes glucose uptake and inhibits hepatic gluconeogenesis. Its pharmacokinetic profile is characterized by a rapid onset of action, typically within 10-20 minutes after subcutaneous injection, a peak effect occurring between 1-3 hours, and a duration of action lasting 3-5 hours. The altered molecular structure decreases the formation of hexamers in the subcutaneous tissue, allowing for quicker dissociation into active monomers and subsequent entry into the capillary network compared to regular human insulin.

History

The development of insulin aspart was driven by the goal of creating insulins that more closely mimic the physiological postprandial insulin response. Researchers at Novo Nordisk utilized site-directed mutagenesis techniques to modify the insulin gene, leading to the creation of this analogue. It received its first regulatory approval from the European Medicines Agency in 1999 and subsequently from the U.S. Food and Drug Administration in 2000. Its introduction represented a significant advancement in diabetes therapy, offering patients greater flexibility in meal timing and improved post-meal glucose control compared to older formulations.

Society and culture

insulin aspart is a major product for Novo Nordisk, a leader in the global diabetes care market. It is available under various brand names worldwide, including Fiasp, a faster-acting formulation that includes niacinamide to enhance absorption. The cost and insurance coverage for insulin aspart have been subjects of significant discussion within healthcare systems, including debates in the U.S. Congress regarding drug pricing. Patient advocacy groups, such as the American Diabetes Association, emphasize the importance of access to this and other insulin analogues for effective diabetes management.